Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 157-169

  Lacoma, Alicia ^a,d   Prat, Cristina ^a,d   Andreo, Felipe ^b,d   Lores, Luis ^c   Ruiz Manzano, Juan ^b,d   Ausina, Vicente ^a,d   Domínguez, Jose ^a,d  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Hospital de Sant Boi   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

C reactive protein; Exacerbation; Neopterin; Procalcitonin; Prognosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; NEOPTERIN; PROCALCITONIN; AUTACOID; CALCITONIN; PROTEIN PRECURSOR;

AGED; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ENTEROBACTERIACEAE; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; FLUORESCENT ANTIBODY TECHNIQUE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; IMMUNOASSAY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SPAIN; SPUTUM; TIME;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOASSAY; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; NEOPTERIN; PNEUMONIA, BACTERIAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPAIN; SPUTUM; TIME FACTORS;

EID: 79960941638     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S16070     Document Type: Article

References (40)

1. Sapey E, Stockley RA. COPD exacerbations. 2: Aetiology. Thorax. 2006;61(3):250-258.
2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10): 847-852.
3. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.
4. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21(2):347-360.
5. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD - a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203-223.
6. Barnes PJ, Chowdhury B, Kharitonov SA, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(1):6-14.
7. Lacoma A, Prat C, Andreo F, Dominguez J. Biomarkers in the management of COPD. Eur Respir Rev. 2009;18(112):96-104.
8. Bathoorn E, Liesker JJ, Postma DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009;4:101-109.
9. Karadag F, Karul AB, Cildag O, Yilmaz M, Ozcan H. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung. 2008;186(6):403-409.
10. Prat C, Dominguez J, Andreo F, et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect. 2006; 52(3):169-177.
11. Muller B, Prat C. Markers of acute inflammation in assessing and managing lower respiratory tract infections: focus on procalcitonin. Clin Microbiol Infect. 2006;12(Suppl 9):8-16.
12. Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37(6):497-507.
13. Pepys MB, Hirschfeld GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805-1812.
14. De Torres J P, Cordoba-Lanus E, Lopez-Aguilar C, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27(5):902-907.
15. Weis N, Almdal T. C-reactive protein - can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmonary disease? Eur J Intern Med. 2006;17(2):88-91.
16. Berdowska A, Zwirska-Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther. 2001;26(5):319-329.
17. Ip M, Rainer TH, Lee N, et al. Value of serum procalcitonin, neopterin, and C-reactive protein in differentiating bacterial from viral etiologies in patients presenting with lower respiratory tract infections. Diagn Microbiol Infect Dis. 2007;59(2):131-136.
18. Barbera JA, Peces-Barba G, Agusti AG, et al. Clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease. Arch Bronconeumol. 2001;37(6):297-316.
19. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398S-401S.
20. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2):347-382.
21. Isenberg HD. Clinical Microbiology Procedures Handbook. 2nd update ed. Washington: ASM Press; 2007.
22. Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975;50(6):339-344.
23. Andreo F, Ruiz-Manzano J, Prat C, et al. Utility of pneumococcal urinary antigen detection in diagnosing exacerbations in COPD patients. Respir Med. 2010;104(3):397-403.
24. Coonrod JD, Rytel M W. Detection of type-specific pneumococcal antigens by counter immunoelectrophoresis. I. Methodology and immunologic properties of pneumococcal antigens. J Lab Clin Med. 1973; 81(5):770-777.
25. Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest. 2001;119(1):243-249.
26. Anthonisen NR, Manfreda J, Warren C P, Hershfeld ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196-204.
27. Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters E F. Systemic effects of smoking. Chest. 2007;131(5):1557-1566.
28. De Kruif MD, Lemaire LC, Giebelen IA, et al. The influence of corti-costeroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med. 2008;34(3):518-522.
29. Perren A, Cerutti B, Lepori M, et al. Influence of steroids on procalci-tonin and C-reactive protein in patients with COPD and community-acquired Pneumonia. Infection. 2008;36(2):163-166.
30. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245-1257.
31. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007;30(3):556-573.
32. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-874.
33. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007;131(4):1058-1067.
34. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum pro-calcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004; 39(2):206-217.
35. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1): 9-19.
36. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998; 339(8):520-532.
37. Kadioglu A, Andrew P W. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 2004; 25(3):143-149.
38. Bircan A, Gokirmak M, Kilic O, Ozturk O, Akkaya A. C-reactive protein levels in patients with chronic obstructive pulmonary disease: role of infection. Med Princ Pract. 2008;17(3):202-208.
39. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma proendothelin predicts survival in exacerbations of COPD. Chest. 2008;134(2):263-272.
40. Lacoma A, Prat C, Andreo F, et al. Usefulness of mid regional proatrial natriuretic peptide in the exacerbations of chronic obstructive pulmonary disease. Clin Chim Acta. 2010;412(5-6):470-475